BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 22723552)

  • 1. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
    Barreyro L; Will B; Bartholdy B; Zhou L; Todorova TI; Stanley RF; Ben-Neriah S; Montagna C; Parekh S; Pellagatti A; Boultwood J; Paietta E; Ketterling RP; Cripe L; Fernandez HF; Greenberg PL; Tallman MS; Steidl C; Mitsiades CS; Verma A; Steidl U
    Blood; 2012 Aug; 120(6):1290-8. PubMed ID: 22723552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
    Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
    Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis.
    De Boer B; Sheveleva S; Apelt K; Vellenga E; Mulder AB; Huls G; Jacob Schuringa J
    Haematologica; 2021 Dec; 106(12):3067-3078. PubMed ID: 33121233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
    Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
    Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL1RAP potentiates multiple oncogenic signaling pathways in AML.
    Mitchell K; Barreyro L; Todorova TI; Taylor SJ; Antony-Debré I; Narayanagari SR; Carvajal LA; Leite J; Piperdi Z; Pendurti G; Mantzaris I; Paietta E; Verma A; Gritsman K; Steidl U
    J Exp Med; 2018 Jun; 215(6):1709-1727. PubMed ID: 29773641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem and progenitor cell alterations in myelodysplastic syndromes.
    Shastri A; Will B; Steidl U; Verma A
    Blood; 2017 Mar; 129(12):1586-1594. PubMed ID: 28159737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
    Shastri A; Choudhary G; Teixeira M; Gordon-Mitchell S; Ramachandra N; Bernard L; Bhattacharyya S; Lopez R; Pradhan K; Giricz O; Ravipati G; Wong LF; Cole S; Bhagat TD; Feld J; Dhar Y; Bartenstein M; Thiruthuvanathan VJ; Wickrema A; Ye BH; Frank DA; Pellagatti A; Boultwood J; Zhou T; Kim Y; MacLeod AR; Epling-Burnette PK; Ye M; McCoon P; Woessner R; Steidl U; Will B; Verma A
    J Clin Invest; 2018 Dec; 128(12):5479-5488. PubMed ID: 30252677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
    Askmyr M; Ågerstam H; Hansen N; Gordon S; Arvanitakis A; Rissler M; Juliusson G; Richter J; Järås M; Fioretos T
    Blood; 2013 May; 121(18):3709-13. PubMed ID: 23479569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.
    Kharas MG; Lengner CJ; Al-Shahrour F; Bullinger L; Ball B; Zaidi S; Morgan K; Tam W; Paktinat M; Okabe R; Gozo M; Einhorn W; Lane SW; Scholl C; Fröhling S; Fleming M; Ebert BL; Gilliland DG; Jaenisch R; Daley GQ
    Nat Med; 2010 Aug; 16(8):903-8. PubMed ID: 20616797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Blume R; Rempel E; Manta L; Saeed BR; Wang W; Raffel S; Ermakova O; Eckstein V; Benes V; Trumpp A; Ho AD; Lutz C
    Leuk Lymphoma; 2018 Sep; 59(9):2201-2210. PubMed ID: 29334844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.